IMPAHCT:
Brief description of study
This phase 2b/3 study will use AV-101 dry powder for oral inhalation in patients with PAH. Procedures include PEs, vital signs, safety labs, right heart caths, echocardiograms, QOL questionnaires, 6MWTs, lung function tests, and PK labs.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting